# Epclusa (sofosbuvir; velpatasvir) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sofosbuvir-velpatasvir

> The FDA approved Epclusa (sofosbuvir; velpatasvir), sponsored by GILEAD SCIENCES, INC. (GILD), on June 10, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Epclusa (sofosbuvir; velpatasvir) |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### June 28, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208341 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20160628, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22

### March 19, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208341 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20200319, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22

### July 14, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208341 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20200714, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22

### June 10, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214187 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20210610, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214187%22

### June 10, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208341 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20210610, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22

### April 27, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208341 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20220427, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22
- openFDA Drugs@FDA: "NDA214187 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220427, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214187%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sofosbuvir-velpatasvir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Epclusa (sofosbuvir; velpatasvir) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sofosbuvir-velpatasvir

```bibtex
@misc{secapidev_pdufa_sofosbuvir_velpatasvir_20261116,
  title        = {Epclusa (sofosbuvir; velpatasvir) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sofosbuvir-velpatasvir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sofosbuvir_velpatasvir_20261116","title":"Epclusa (sofosbuvir; velpatasvir) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sofosbuvir-velpatasvir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
